Study detail
RecruitingPhase 3
A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection
Vanda Pharmaceuticals
Summary
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- No
Detailed criteria
Inclusion Criteria: * Males or females 18 to 65 years of age (inclusive) * Diagnosed with schizophrenia per DSM-5 criteria * In need of ongoing psychiatric treatment Exclusion Criteria: * DSM-5 diagnosis of a psychiatric disorder other than schizophrenia that was the primary focus of treatment within the previous six months
Interventions
- Drugiloperidone
iloperidone LAI
- Drugplacebo
matching placebo
Locations (22)
- Vanda Investigational SiteRogers, Arkansas
- Vanda Investigational SiteCosta Mesa, California
- Vanda Investigational SiteLemon Grove, California
- Vanda Investigational SiteOceanside, California
- Vanda Investigational SitePico Rivera, California
- Vanda Investigational SiteSan Diego, California